R&D Trends

OncoSec Medical, University of Washington ink research agreement

Friday, November 21, 2014 11:20 AM

OncoSec Medical, a San Diego-based company developing DNA-based intratumoral cancer immunotherapies, has entered a sponsored research agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.

More... »


Study: global spending on medicines to increase 30% by 2018, to $1.3 trillion

Thursday, November 20, 2014 01:38 PM

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.

More... »

CenterWatch

Genomics England calls on the U.K. research community

Wednesday, November 19, 2014 02:25 PM

Genomics England is inviting applications to join a new Clinical Interpretation Partnership from U.K. researchers, NHS Clinicians and those in training where they will work on the unique data resource from the 100,000 Genomes Project. The goal of the Genomics England Clinical Interpretation Partnership (GeCIP) is to bring together the best researchers in the U.K., alongside their key international collaborators, to ensure maximized potential to gaining new biological insights into rare inherited diseases, cancers and infectious disease.

More... »

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014 02:18 PM

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

More... »

Tufts CSDD: Developing, winning marketing approval for a new drug now cost $2.6 billion

Tuesday, November 18, 2014 02:22 PM

Developing and gaining marketing approval for a new prescription medicine, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development (CSDD).

More... »

Geron, Janssen collaborate to develop and commercialize imetelstat

Monday, November 17, 2014 02:36 PM

Geron, a Menlo Park, Calif.-based clinical stage biopharmaceutical company, has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies and other human therapeutics uses.

More... »

Boehringer Ingelheim, WellPoint, HealthCore collaborate

Monday, November 17, 2014 02:34 PM

Boehringer Ingelheim Pharmaceuticals (BIPI); WellPoint, an Indiana-based, U.S. health benefit company; and HealthCore, a Wilmington, Del.-based wholly-owned subsidiary of WellPoint, are launching a research project to identify and address unmet medical needs.

More... »

Merck, Pfizer ink alliance on anti-PD-L1

Monday, November 17, 2014 02:28 PM

Merck has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

More... »

Bone Therapeutics, Kasios collaborate on optimization of spinal fusion procedures

Monday, November 17, 2014 02:27 PM

Bone Therapeutics, a Belgium regenerative therapy company addressing unmet medical needs releated to bone diseases and orthopaedics, and Kasios, a French synthetic bone substitute specialist, have announce a two-year collaboration to develop a novel product for spinal fusion procedures. The collaboration combines Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasios's synthetic micro-granules bone substitute. The project is subsidized by the government of the Walloon Region.

More... »

GHIT Fund calls for greater collaboration on infectious diseases

Friday, November 14, 2014 10:43 AM

The Global Health Innovative Technology (GHIT) Fund and the Embassy of Japan have called for greater cross-border collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases, including tuberculosis, malaria, HIV/AIDS and neglected tropical diseases.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs